Servier signs $1.55B upfront deal for Edgewise’s muscular dystrophy assetsnews2026-06-01T12:31:49+00:00June 1st, 2026|Endpoints News|
#ASCO26: AstraZeneca’s triplet combo succeeds in liver cancer subgroupnews2026-06-01T12:00:27+00:00June 1st, 2026|Endpoints News|
Lilly licenses GLP-2 asset from Korean biotech Hanmi for $75M upfrontnews2026-06-01T10:43:21+00:00June 1st, 2026|Endpoints News|
#ASCO26: Erleada succeeds in early-stage prostate cancer study, but questions remainnews2026-06-01T10:19:50+00:00June 1st, 2026|Endpoints News|
Oculis’ eye drops for diabetic macular edema flunk Phase 3 testnews2026-06-01T06:58:46+00:00June 1st, 2026|Endpoints News|
#ASCO26: Yes, Revolution Medicines’ pancreatic cancer data are that goodnews2026-05-31T12:06:24+00:00May 31st, 2026|Endpoints News|
#ASCO26: Summit, Akeso drug reduces death by 34% in China lung cancer studynews2026-05-31T12:00:46+00:00May 31st, 2026|Endpoints News|
#ASCO26: Personalized cancer vaccines may help brain cancer patients live longernews2026-05-31T00:15:37+00:00May 31st, 2026|Endpoints News|
#ASCO26: Grail’s cancer blood test isn’t ready for widespread use, experts saynews2026-05-30T23:59:07+00:00May 30th, 2026|Endpoints News|
Can AI do scientific research?; The ‘magic bullet’ search has faded in immunotherapy; and more news2026-05-30T10:00:08+00:00May 30th, 2026|Endpoints News|
